Health Stocks Trade Lower: GLH, AT1 and IMM Shares in Focus Today

Sonal Goyal

10 November 2026 07:04 PM AEDT

Health Stocks Trade Lower: GLH, AT1 and IMM Shares in Focus Today

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Atomo Diagnostics (ASX:AT1) fell 10.71% to $0.013 during the trading session.
Global Health (ASX:GLH) dropped 10.00% to $0.045, and Immutep (ASX:IMM) fell 7.69% to $0.024.
The S&P/ASX 200 rose 1.34% over the same session.

Three ASX healthcare companies traded lower during the 10 November 2026 trading session, while the S&P/ASX 200 was higher by 1.34%, or 121.20 points, at 9,150.90. Global Health Ltd (ASX:GLH), Atomo Diagnostics Ltd (ASX:AT1) and Immutep Ltd (ASX:IMM) operate in healthcare software, diagnostics and immunotherapy. Each company's latest update is covered in its own section below.

Global Health Ltd (ASX:GLH)

Global Health shares were down 10.00% at $0.045 during the session. Its Appendix 4C and quarterly report, released on 26 October 2026, showed operating cash outflow of $828,000 for the September quarter, an improvement of $237,000 on the prior year quarter.

For the 12 months to September 2026, operating cash outflow was $553,000, a 57% reduction, and staff and contractor expenses fell by $739,000. The company said major deals are typically decided in the December and March quarters.

Atomo Diagnostics Ltd (ASX:AT1)

Atomo shares fell 10.71% to $0.013 during the session. Its Q1 FY27 Appendix 4C and quarterly report, released on 29 October 2026, reported Revenue of $1.63 million, up 140% on the prior quarter.

FebriDx orders reached $680,000, up 314% year on year, and cash on hand at quarter end was $2.67 million. The company signed a Generation 4 HIV development agreement and a Partnership with Upfront Diagnostics for a rapid brain disease test.

Immutep Ltd (ASX:IMM)

Immutep shares were down 7.69% at $0.024 during the session. Its update dated 9 November 2026 covered early Phase I data for IMP761, its LAG-3 agonist antibody, presented at ACR Convergence 2026.

The study in 60 healthy volunteers showed statistically significant inhibition of T-cell-driven immune responses, was well tolerated across all seven dose levels, and the pharmacokinetic profile supports a four-week dosing interval.

Final Word

The three companies reported on different dates and in different areas of healthcare, and their share price moves were recorded separately during the session. Each company's next report will provide the latest figures.

FAQs

Q: What were Atomo's FebriDx orders in the quarter?

A: FebriDx orders reached $680,000, up 314% year on year.

Q: How much did Global Health's operating cash outflow fall over 12 months?

A: It fell 57% to $553,000 for the 12 months to September 2026.

Q: How many volunteers were in Immutep's Phase I study?

A: The study enrolled 60 healthy volunteers.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.